Co-Development Agreements

The National Cancer Institute's Technology Transfer Center (TTC) recognizes the importance of co-development in order to translate early-stage discoveries to outside entities to benefit public health. In support of this goal, the TTC establishes formal collaborative agreements with industry, academia, and non-profits to facilitate co-development through the exchange and development of research materials, knowledge, and technologies.

The TTC uses three different co-development agreements to help industry and academia interact and partner with National Institutes of Health laboratories and scientists to support technology development activities:

<table>
<thead>
<tr>
<th>Agreements</th>
<th>Purpose</th>
<th>Essential Elements</th>
</tr>
</thead>
</table>
| Collaboration Agreement (CA)        | Permits a two-way exchange of materials and information, and assumes exchange of results and/or conclusions will occur between NIH and companies, universities, state/local governments, Federal labs, and non-profits. | - Combines terms of a CDA and MTA  
- Simplified research plan  
- Exchange of new material created during the collaboration is addressed  
- No funding from the outside party allowed  
- No license option  
- Rights to foreground IP are not addressed  
- Human and non-human materials covered |
<table>
<thead>
<tr>
<th>Agreements</th>
<th>Purpose</th>
<th>Essential Elements</th>
</tr>
</thead>
</table>
| Cooperative Research and Development Agreement (CRADA) | Permits co-development of NIH or outside invention involving companies, universities, state/local governments, Federal labs, and non-profits. | **For NIH:**
- May receive funds or in-kind contributions for collaborative research project
- May provide confidentiality for research results up to five years after development  

**For Collaborator:**
- **Option to exclusively license any inventions that are developed by a Federal laboratory employee(s) as part of the collaborative research**
  - Access to unique reagents and resources
  - Access to scientific and regulatory expertise
  - Access to Federal lab
  - Covers investigational data, drug, diagnostic, or device
  - No funding from the outside party required
  - No option to license foreground IP
  - Clinical and non-clinical
  - Addresses regulatory issues and monitoring
  - Addresses Personally Identifiable Information (PII) |
| Clinical Trial Agreement (CTA)                       | Transfers material into NIH for research in Human Subjects from companies, state/local governments, non-profits, universities |                                                                                                                                                      |